22 May 2013
Keywords: smc, approves, novartis, tasigna, ph, cml, scottish
Article | 16 June 2008
The Scottish Medicines Consortium has approved Swiss drug major Novartis' Tasigna (nilotinib) for the treatment of chronic phase
Philadelphia chromosome ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 June 2008
21 May 2013
© 2013 thepharmaletter.com